Normal view MARC view ISBD view

Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing.

MedStar author(s):

Citation: Genetics in Medicine. 23(12):2335-2341, 2021 12.PMID: 34282303Department: MedStar Health | PharmacogenomicsForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Pharmacogenetics | *Pharmacogenomic Testing | Drug Prescriptions | Genetic Testing | Humans | Pharmacogenetics/mt [Methods] | Precision Medicine/mt [Methods]Year: 2021 Local holdings: Available online from MWHC library: 2002 - 2011ISSN:

1098-3600

Name of journal: Genetics in medicine : official journal of the American College of Medical GeneticsAbstract: CONCLUSION: These findings should inform the establishment of future implementation efforts at institutions considering a pre-emptive PGx testing program. Copyright (c) 2021. The Author(s), under exclusive licence to the American College of Medical Genetics and Genomics.METHODS: In this report, we compare and contrast implementation strategies for pre-emptive PGx testing by 15 early-adopter institutions. We surveyed these groups, collecting data on testing approaches, team composition, and workflow dynamics, in addition to estimated third-party reimbursement rates.PURPOSE: The increased availability of clinical pharmacogenetic (PGx) guidelines and decreasing costs for genetic testing have slowly led to increased utilization of PGx testing in clinical practice. Pre-emptive PGx testing, where testing is performed in advance of drug prescribing, is one means to ensure results are available at the time of prescribing decisions. However, the most efficient and effective methods to clinically implement this strategy remain unclear.RESULTS: We found that while pre-emptive PGx testing models varied across sites, institutions shared several commonalities, including methods to identify patients eligible for testing, involvement of a precision medicine clinical team in program leadership, and the implementation of pharmacogenes with Clinical Pharmacogenetics Implementation Consortium guidelines available. Finally, while reimbursement rate data were difficult to obtain, the data available suggested that reimbursement rates for pre-emptive PGx testing remain low.All authors: Aquilante CL, Beitelshees AL, Cavallari LH, Cicali EJ, Dalton R, Duarte JD, Duong BQ, Elchynski AL, Empey PE, Hicks JK, IGNITE Network Pharmacogenetics Working Group, Johnson JA, Lee JC, Obeng AO, Pasternak AL, Petry NJ, Pratt VM, Ramsey LB, Smith DM, Tuteja S, Van Driest SL, Wiisanen KOriginally published: Genetics in Medicine. 23(12):2335-2341, 2021 Dec.Fiscal year: FY2022 Digital Object Identifier:

https://dx.doi.org/10.1038/s41436-021-01269-9

Date added to catalog: 2021-07-26

Holdings ( 1 )
Title notes ( 6 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	34282303	Available		34282303

Available online from MWHC library: 2002 - 2011

CONCLUSION: These findings should inform the establishment of future implementation efforts at institutions considering a pre-emptive PGx testing program. Copyright (c) 2021. The Author(s), under exclusive licence to the American College of Medical Genetics and Genomics.

METHODS: In this report, we compare and contrast implementation strategies for pre-emptive PGx testing by 15 early-adopter institutions. We surveyed these groups, collecting data on testing approaches, team composition, and workflow dynamics, in addition to estimated third-party reimbursement rates.

PURPOSE: The increased availability of clinical pharmacogenetic (PGx) guidelines and decreasing costs for genetic testing have slowly led to increased utilization of PGx testing in clinical practice. Pre-emptive PGx testing, where testing is performed in advance of drug prescribing, is one means to ensure results are available at the time of prescribing decisions. However, the most efficient and effective methods to clinically implement this strategy remain unclear.

RESULTS: We found that while pre-emptive PGx testing models varied across sites, institutions shared several commonalities, including methods to identify patients eligible for testing, involvement of a precision medicine clinical team in program leadership, and the implementation of pharmacogenes with Clinical Pharmacogenetics Implementation Consortium guidelines available. Finally, while reimbursement rate data were difficult to obtain, the data available suggested that reimbursement rates for pre-emptive PGx testing remain low.

English